Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | STAT3 | P40763 | 1/20 | 0.36 |
| ▸ | FDPS | P14324 | 2/20 | 0.36 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.36 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.36 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.36 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.36 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.36 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.36 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10538451 | 1.00 | CA12 (0.38) | CA12CA9CA1ALDH1A1CYP3A4 | |
| SCHEMBL11363251 | 1.00 | CA12 (0.38) | CA12CA9CA1ALDH1A1CYP3A4 | |
| SCHEMBL10538441 | 1.00 | CA12 (0.38) | CA12CA9CA1ALDH1A1CYP3A4 | |
| SCHEMBL10725680 | 1.00 | CA12 (0.38) | CA12CA9CA1ALDH1A1CYP3A4 | |
| SCHEMBL10759972 | 1.00 | CA12 (0.38) | CA12CA9CA1ALDH1A1CYP3A4 | |
| SCHEMBL1769852 | 1.00 | CA12 (0.38) | CA12CA9CA1ALDH1A1CYP3A4 | |
| SCHEMBL9485780 | 1.00 | CA12 (0.38) | CA12CA9CA1ALDH1A1CYP3A4 | |
| SCHEMBL3577983 | 0.93 | LMNA (0.40) | CA12CA9CA1ALDH1A1CYP3A4 | |
| SCHEMBL3575734 | 0.93 | LMNA (0.40) | CA12CA9CA1ALDH1A1CYP3A4 | |
| SCHEMBL17233364 | 0.91 | CA9 (0.43) | CA12CA9CA1ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7846903-B2 | cubic liquid crystal formulation containing an amphiphilic compound such as 1-O-(5,9,13-trimethyltetradecyl)erythritol and a drug ( excluding a lysosomal enzyme) or cosmetic embedded in the cubic liquid crystal; time release agent | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2010-12-07 | — | — | US | disclosed |
| US-20080113923-A1 | Type II Cubic Liquid Crystal Composition | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE (JP) | 2008-05-15 | — | — | US | disclosed |
| EP-1813287-A1 | TYPE II CUBIC LIQUID CRYSTAL COMPOSITION | National Institute of Advanced Industrial Science and Technology (JP) | 2007-08-01 | — | — | EP | disclosed |
| US-4824971-A | 2-allylchromans | HOFFMAN-LA ROCHE INC. (US) | 1989-04-25 | — | — | US | disclosed |
| US-4806661-A | Chromanemelonate esters | HOFFMANN-LA ROCHE INC. (US) | 1989-02-21 | — | — | US | disclosed |
| US-4752646-A | 2-halochromans | HOFFMANN-LA ROCHE INC. (US) | 1988-06-21 | — | — | US | disclosed |
| US-4694084-A | Glycerol ether phosphatides | HOFFMANN-LA ROCHE INC. (US) | 1987-09-15 | — | — | US | disclosed |
| US-4654348-A | Pyrazolo[4,3-d]pyrimidine derivative, process for its production, antihyperlipidemic agent containing it, its intermediate, and process for the production of the intermediate | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1987-03-31 | — | — | US | disclosed |
| EP-0157415-A2 | Pyrazolo[4,3-d] pyrimidine derivative process for its production antihyperlipidemic agent containing it, its intermediate, and process for the production of the intermediate | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1985-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113923-A1 | Type II Cubic Liquid Crystal Composition | AQP1, AQP3, SCO2 | CA12 34/4885CA9 79/4885CA1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.